For over 10 years we have been using a wide array of technologies to detect cancer biomarkers. In the last year we transitioned from using third party technologies to develop our own platform. We are building on our extensive experience in biomarker detection and clinical oncology. We changed the name of our company to reflect our new focus.
Our state-of-the-art R&D facility is focused in the development of the LightBOX, an automated point-of-care device capable of capturing, staining, and imaging circulating tumor cells from blood derived samples.
Our facilities were originally designed and built for Austin Biological Laboratories, an innovative pioneer in biological research in Austin, Texas.
Leonardo Forero, M.D. Medical Director
Dr. Leonardo Forero is a board certified Medical Oncologist. He served as a research fellow in Immunology and completed his internship and residency in Internal Medicine at the University of Texas Southwestern Medical School and St. Paul University Hospital in Dallas, Texas. He trained as a Medical Oncologist with emphasis in Developmental Therapeutics (Drug Development) at the University of Texas Health Science Center at San Antonio. Dr. Leonardo Forero has presented, authored and co-authored a number of scientific articles in peer-reviewed medical journals and scientific meetings. Dr. Forero has extensive experience in clinical research. He has served as principal and co-principal investigator in a large number of clinical trials for new oncology drugs and early cancer screening tests. He is a faculty member at the Medical School at Texas Tech University Health Sciences Center. He is also the primary investigator for most of the clinical trials conducted at Texas Oncology in West Texas.
Andres Forero, Ph.D. CEO
Dr. Andres Forero has over 20 yrs of experience in engineering, management, consulting, and investments. He holds degrees in Mechanical Engineering (B.S.M.E.), Business Administration (MBA-Finance), Liberal Arts (M.A), and a Ph.D. in Public Policy from the University of Texas at Austin. He has been working in the biotech industry for over 10 years focusing on CTC capture and cancer biomarker technologies.